TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05459454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A digital health program for patients with Breast Cancer
Description: A digital solution that supports healthy lifestyle changes, provides disease and side effect education as well as daily tasks for patients diagnosed with breast cancer.
Study: NCT04750876

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional support
Description: Patients in the Conventional support randomisation arm will follow the usual care of amputee patients in the vascular surgery department. They will be cared for by the surgeon, nurses and nursing auxiliaries, who will provide individualised care (nursing care, mobilisation, pain management, technical care, etc.), listening and support.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific care, including the intervention of a psychologist and a physical therapist.
Description: In the case where the patient is in the Specific care, including the intervention of a psychologist and a physical therapist. arm, the usual care will be associated with :~* consultations with a psychologist~* The patient will also be cared for on a daily basis by a physical therapist.
Study: NCT05539768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS-IT101
Description: Adoptive transfer of 1x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
Study: NCT05863104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium Bromide (GPB) Cream
Description: Application of cream to each axilla
Study: NCT06369103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will receive dexmedetomidine at a dose of 0.5-1.0 mcg/kg over 5-10 minutes, then a maintenance infusion rate of 0.2-0.5 mcg/kg/min when the bispectral index (BIS) value is between 70 and 80.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients will receive propofol at a dose of 0.25-0.5 mg/kg over 5-10 minutes, then a maintenance Infusion rate of 0.5-2 mg/kg/hr when the bispectral index (BIS) value is between 70 and 80.
Study: NCT05287945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orellanine
Description: Orellanine administered intravenously
Study: NCT05259722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib
Description: Cream for topical application 20 mg/g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toctino
Description: 1 capsule toctino 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
Study: NCT05094791

Intervention type: DEVICE
Intervention: Telescoping Lag Screw
Description: Intertrochanteric fracture fixation using Arthrex Hip Nail with Telescoping Lag Screw

Intervention type: DEVICE
Intervention: Standard lag Screw
Description: Intertrochanteric fracture fixation using Zimmer Natural Nail Cephalomedullary Nail using standard lag screw

Intervention type: DEVICE
Intervention: Standard lag screw with addition of worm screw
Description: Intertrochanteric fracture fixation using Smith and Nephew TRIGEN INTERTAN with addition of worm screw
Study: NCT05878457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System
Description: Treatment will consist 12 approximately-three-minute sessions on each of three treatment days within a seven-day period. To promote participant adherence and retention, treatment days will not need to be contiguous. A single session consists of 600 pulses delivered to the dmPFC at an intensity of 120% resting motor threshold (rMT). 50 hz triphasic bursts will be delivered for two seconds, followed by an 8 second inter-train interval. Trains will be repeated every 10 seconds, 10 times total, for a total of 190 seconds per session. An intersession interval of at least 15 minutes will be employed between each of the 12 sessions. Each treatment day will thus last approximately 3-4 hours in duration.
Study: NCT05353699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation strategies
Description: We will adopt implementation strategies,which include Capacity-building strategies, Supervision, Integration strategies, Implementation process strategies, Dissemination strategies, Scale-up strategies.Firstly,Capacity-building strategies include:recruit, designate, and train for leadership; work with educational institutions.Secondly,Supervision includes provide clinical supervision;Thirdly,Integration strategies include: remind clinicians; use data warehousing techniques.Fourthly,Implementation process strategies include: identify and prepare champions; identify early adopters; inform local opinion leaders; involve patients/consumers and family members; obtain and use patients/consumers and family feedback.Fifthly,Dissemination strategies include: make training dynamic.Finally,Scale-up strategies include: use train-the-trainer strategies;place innovation on fee for service lists/formularies.
Study: NCT04790136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA-015
Description: administration followed by PK blood sampling

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAC C-052 Cannabidiol / NRF 22.10 Oily cannabidiol solution 100 mg/ml
Description: administration followed by PK blood sampling
Study: NCT05377788

Intervention type: DRUG
Intervention: Lazertinib
Description: Treatment of EGFR T790M mutant-positive local progressive or metastatic non-small cell lung cancer patients who have previously been treated with EGFR

Intervention type: DRUG
Intervention: Lazertinib
Description: Treatment of EGFR T790M mutant-positive local progressive or metastatic non-small cell lung cancer patients who have previously been treated with EGFR
Study: NCT05439161

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: 2 types of filtering glaucoma surgeries (classic trabeculectomy as gold standard, and newer XEN glaucoma microstent) are compared against each other in a prospective multicentric randomized study

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: 2 types of filtering glaucoma surgeries (classic trabeculectomy as gold standard, and newer XEN glaucoma microstent) are compared against each other in a prospective multicentric randomized study
Study: NCT05732090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic exercise program
Description: therapeutic exercise program (3 sessions/week/two months).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic exercise program
Description: therapeutic exercise program (3 sessions/week/two months).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diaphragmatic myofascial release
Description: therapeutic exercise program in addition to diaphragmatic myofascial release (3 sessions/week/two months).
Study: NCT05689970

Intervention type: DIAGNOSTIC_TEST
Intervention: AI platform to detect ST elevation in ECG
Description: A clinical decision support software as a medical device that detects whether a patient has ST elevation due to acute myocardial ischemia or due to another etiology based upon the input of one or more ECGs and other clinical data obtained at the point-of-care.

Intervention type: DIAGNOSTIC_TEST
Intervention: AI platform to detect ST elevation in ECG
Description: A clinical decision support software as a medical device that detects whether a patient has ST elevation due to acute myocardial ischemia or due to another etiology based upon the input of one or more ECGs and other clinical data obtained at the point-of-care.
Study: NCT06466629

Intervention type: BIOLOGICAL
Intervention: Triaxis, Sanofi Pasteur
Description: tetanus, diphtheria, acellular pertussis (aP) (Tdap) vaccine

Intervention type: BIOLOGICAL
Intervention: Triaxis, Sanofi Pasteur
Description: tetanus, diphtheria, acellular pertussis (aP) (Tdap) vaccine

Intervention type: BIOLOGICAL
Intervention: Triaxis, Sanofi Pasteur
Description: tetanus, diphtheria, acellular pertussis (aP) (Tdap) vaccine
Study: NCT05540002

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Quell
Description: Participants will receive 1 hour of continuous stimulation during each therapy session. Subjects are asked to complete a minimum of 3 sessions per day.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low Intensity Quell
Description: Participants will receive only three 2-minute periods of stimulation (at 0, 28, 58 minutes) during each 60-minute therapeutic session. Subjects are asked to complete a minimum of 3 sessions per day.
Study: NCT04046107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered as an intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered as an intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered as an intravenous (IV) infusion
Study: NCT05121480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815
Description: EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815
Description: EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815
Description: EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815
Description: EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule
Study: NCT01093274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Picosulphate
Description: 2 Sachets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol
Description: 3 Liters solution
Study: NCT05894174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Board Game
Description: Food Hunter board game intervention, which includes various nutrient cards and question cards and is played with pawns and dice, will be played with children for approximately 4 weeks, one day a week and one session (40 minutes) with the researcher dietitian. By talking about the nutrients in the game on the game cards, children will be able to recognize the nutrients and important points will be emphasized for the participants with the answers to the cards containing various questions about healthy nutrition.
Study: NCT06319313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101
Description: JMT101, 6 mg/kg, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). or 9 mg/kg, IV infusion once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101
Description: JMT101, 6 mg/kg, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). or 9 mg/kg, IV infusion once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 50 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 75 mg/m2, IV infusion once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB1801
Description: 75 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 100 mg/m2, IV infusion once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB1801
Description: 75 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 100 mg/m2, IV infusion once every 3 weeks.
Study: NCT05137548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-2173 50 mg
Description: ATI-2173 is a liver-targeted phosphoramidate oral prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 300Mg Oral Tablet
Description: Tenofovir is an oral nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus. It will be dosed as a tablet by mouth
Study: NCT04854434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Participants will receive selinexor oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Participants will receive selinexor oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive pembrolizumab intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine
Description: Participants will receive trifluridine oral tablets as SOC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tipiracil
Description: Participants will receive tipiracil oral tablets as SOC.
Study: NCT05371977

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: trabeculectomy glaucoma surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Sclerectomy
Description: deep sclerectomy glaucoma surgery
Study: NCT05138016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft exosuit
Description: Progressive cardiovascular exercise testing with soft exosuit assistance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Soft exosuit
Description: Progressive cardiovascular exercise testing.
Study: NCT05352815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IcoSema
Description: Participants will receive once weekly IcoSema subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin icodec
Description: Participants will receive once weekly Insulin icodec subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
Study: NCT06490640

Intervention type: OTHER
Intervention: Spontaneous subarachnoid haemorrhage survival cohort
Description: consists of surviving patients

Intervention type: OTHER
Intervention: Spontaneous subarachnoid haemorrhage mortality cohort
Description: consists of deceased patients
Study: NCT04461262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Camstent Coated Catheter
Description: The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed. The device is CE marked

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard Care
Description: Uncoated Foley catheter
Study: NCT04654442

Intervention type: DIAGNOSTIC_TEST
Intervention: TestNPass
Description: Patients will undergo saliva sampling. Grenoble University Hospital lab will perform diagnosis using TestNPass IVDMD. Results won't be used for patient care (only recorded for RESEARCH purpose).

Intervention type: DIAGNOSTIC_TEST
Intervention: TestNPass
Description: Patients will undergo saliva sampling. Grenoble University Hospital lab will perform diagnosis using TestNPass IVDMD. Results won't be used for patient care (only recorded for RESEARCH purpose).
Study: NCT04725695

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Viscous Lidocaine
Description: The patients will be randomized to either viscous lidocaine or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viscous Lidocaine
Description: The patients will be randomized to either viscous lidocaine or placebo
Study: NCT05224063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized CEN-targeted rTMS
Description: Delivers patterned magnetic stimulation based on individualized CEN targeting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuronavigated rTMS
Description: Delivers patterned magnetic stimulation based on MRI images

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scalp-targeted rTMS
Description: Delivers patterned magnetic stimulation based on BEAM F3 targeting

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS
Description: Delivers placebo magnetic stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS
Description: Delivers placebo magnetic stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS
Description: Delivers placebo magnetic stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Delivers placebo magnetic stimulation
Study: NCT05923632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dijital Game and Health Education
Description: After the children in the experimental group are informed about the digital game designed according to The The Information-Motivation-Behavioral Skills Model (IMB) in diabetes management, active participation of the children in the digital game will be ensured for 9 weeks; and participation status will be followed in the background of the game. At the end of 9 weeks, children will be asked to complete all stages of the game. Children who do not complete the game will be contacted once a week in line with their background follow-up and reminders will be made.
Study: NCT06414525

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: abdominal massage
Description: It will include patients that will receive abdominal massage; the frequency and duration of the massage will be arranged as 3 sessions per week, with each session lasting an average of 20-25 minutes for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: visceral manipulation
Description: It will include patients that will receive visceral manipulation; the frequency and duration of the technique will be arranged as 3 sessions per week, with each session lasting an average of 20-25 minutes for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: instructions on daily, dietary , toilet , and physical activity habits
Description: It will include patients that will receive behavioral therapy: defecation mechanism and informing about negative attitudes and behaviors towards defecation), lifestyle advice (diet, water consumption, fiber food, etc.), teaching effective defecation posture, and timed toilet training.
Study: NCT05307484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serious game
Description: This is a serious game in the form of a mobile application, designed to educate adults on dengue prevention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dengue prevention website
Description: This is a website containing information regarding dengue prevention.
Study: NCT05144750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fruit and Vegetable Prescription
Description: The intervention adds a $50 monthly fruit and vegetable voucher, and text reminder and educational text messages (recipes/tips) to the Standard of Care for patients.~Standard Care for Patients at OCH: Patients will be able to regularly meet with their healthcare team.~Fruit and Vegetable Incentive: During the 8-month intervention period, registered program participants can receive $50 monthly through the reloadable Walmart gift card, which can only be used to purchase fresh fruits and vegetables. The total incentive will be $400 for the eight-month program.~Text Communication: Wholesome Wave will share text reminders to shop and utilize incentives. Wholesome Wave will also share text messages that are consistent with the messages that the OCH dietitians are offering in their standard care, including recipes and tips.
Study: NCT05267275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extended resection with splenic flexure mobilization
Description: During the operation, the splenic flexure of the colon was first freed, and then the physiological adhesion site of the sigmoid colon was located. Routine laparoscopic or open rectal cancer radical resection (D3 dissection + high ligation) was performed. The proximal end of the colon is disconnected 10-15cm away from the physiological adhesion site of the sigmoid colon. The anastomosis method was manual anastomosis or stapler anastomosis, and a prophylactic ileal loop ostomy was routinely performed.
Study: NCT04664361

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide mononucleotide
Description: Daily supplementation with NMN at 250 and 500 mg for 38 days in total

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide mononucleotide
Description: Daily supplementation with NMN at 250 and 500 mg for 38 days in total

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily supplementation with placebo for 38 days in total
Study: NCT05914636

Intervention type: BIOLOGICAL
Intervention: analysis of foecal microbiota
Description: An analysis of foecal microbiota including taxonomic and metabolomic analysis will be performed and compared between ruptured and unruptured patient.~confundens factors as diet, obesity for microbiota and as smoking, hypertension, size for aneurysm ruptured will be sampled and independence will be analyzed.

Intervention type: BIOLOGICAL
Intervention: analysis of foecal microbiota
Description: An analysis of foecal microbiota including taxonomic and metabolomic analysis will be performed and compared between ruptured and unruptured patient.~confundens factors as diet, obesity for microbiota and as smoking, hypertension, size for aneurysm ruptured will be sampled and independence will be analyzed.
Study: NCT05378256

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical scales of CIPN
Description: Patients with lymphoma will be evaluated before chemotherapy (T1), after 4 cycles (T2), at the end of the chemotherapy treatment (If more than 4 cycles) (T3) and 6 month after the end of chemotherapy (T4).